Laboratorios Farmaceuticos Rovi, S.A.

BME:ROVI 株式レポート

時価総額:€3.2b

Laboratorios Farmaceuticos Rovi マネジメント

マネジメント 基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Juan Lopez-Belmonte Encina

最高経営責任者

€1.3m

報酬総額

CEO給与比率55.2%
CEO在任期間17.9yrs
CEOの所有権n/a
経営陣の平均在職期間データなし
取締役会の平均在任期間5.6yrs

経営陣の近況

We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet

Jun 17
We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet

Recent updates

Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 10
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For

Oct 21
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For

Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Aug 29
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Jul 15
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet

Jun 17
We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet

Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price

May 08
Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Apr 17
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?

Feb 14
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?

Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

Dec 21
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?

Nov 03
Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?

Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly

Aug 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly

Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate

Jul 14
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate

Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

May 26
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?

May 05
Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?

Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate

Apr 11
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate

Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

Feb 22
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued

Dec 10
An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely

Nov 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely

Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?

Sep 15
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?

Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Aug 28
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

Jun 15
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease

Feb 13
I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease

Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Jan 02
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Dec 12
A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

Nov 02
Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Sep 24
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

Jun 02
Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Apr 06
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%

Mar 15
Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%

If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late

Feb 16
If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late

Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?

Jan 26
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years

Dec 14
Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years

Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?

Nov 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?

CEO報酬分析

Laboratorios Farmaceuticos Rovi の収益と比較して、Juan Lopez-Belmonte Encina の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

€165m

Jun 30 2024n/an/a

€148m

Mar 31 2024n/an/a

€138m

Dec 31 2023€1m€743k

€170m

Sep 30 2023n/an/a

€197m

Jun 30 2023n/an/a

€186m

Mar 31 2023n/an/a

€194m

Dec 31 2022€1m€728k

€200m

Sep 30 2022n/an/a

€176m

Jun 30 2022n/an/a

€183m

Mar 31 2022n/an/a

€182m

Dec 31 2021€2m€327k

€153m

Sep 30 2021n/an/a

€113m

Jun 30 2021n/an/a

€82m

Mar 31 2021n/an/a

€71m

Dec 31 2020€561k€330k

€61m

Sep 30 2020n/an/a

€55m

Jun 30 2020n/an/a

€53m

Mar 31 2020n/an/a

€46m

Dec 31 2019€541k€320k

€39m

Sep 30 2019n/an/a

€33m

Jun 30 2019n/an/a

€27m

Mar 31 2019n/an/a

€18m

Dec 31 2018€908k€312k

€18m

Sep 30 2018n/an/a

€16m

Jun 30 2018n/an/a

€9m

Mar 31 2018n/an/a

€18m

Dec 31 2017€524k€303k

€17m

報酬と市場: Juanの 総報酬 ($USD 1.40M ) は、 Spanish市場 ($USD 1.52M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Juanの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Juan Lopez-Belmonte Encina

17.9yrs

在職期間

€1,346,000

報酬

Mr. Juan Lopez-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007 and served as its President from October 2020 to October 2022. He has been with L...


取締役

名称ポジション在職期間報酬所有権
Juan Lopez-Belmonte Encina
Chairman & CEO17.4yrs€1.35mデータなし
Ivan Lopez-Belmonte Encina
Second Deputy Chairman & GM of Commercial and Development17.4yrs€552.00kデータなし
Javier Lopez-Belmonte Encina
First Deputy Chairman17.4yrs€554.00kデータなし
Marcos Pena Pinto
Independent Director5.6yrs€80.00kデータなし
Fatima Garcia
Independent Director5yrs€80.00kデータなし
Marina del Tellez
Director2.6yrs€80.00kデータなし
Teresa Santamaria
Independent Director2yrs€80.00kデータなし

5.6yrs

平均在職期間

経験豊富なボード: ROVIの 取締役会経験豊富 であると考えられます ( 5.6年の平均在任期間)。


企業分析と財務データの現状

データ最終更新日(UTC時間)
企業分析2024/12/24 07:10
終値2024/12/24 00:00
収益2024/09/30
年間収益2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Laboratorios Farmaceuticos Rovi, S.A. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18

アナリスト機関
Álvaro Arístegui EchevarríaAhorro Corporación
Guilherme SampaioBanco BPI, S.A.
Javier Esteban LarioBanco de Sabadell. S.A.